GOLGA6C

Across TCGA pan-cancer cohorts, GOLGA6C Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GOLGA6C data layer compared with 20 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher GOLGA6C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6C expression acts as an unfavorable survival marker.

SKCM, PRAD, and UCEC are the cancer types where GOLGA6C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	III,IV	0.230	0.721	.004	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GOLGA6C–SKCM (OS)

Open the SKCM breakdown →